Loading stock data…
$0.88-0.18 (-17.27%)
Co-Diagnostics, Inc.
Co-Diagnostics, Inc. in the Healthcare sector is trading at $0.88 with a market capitalization of $7M. Wall Street consensus targets $4.00 (1 analysts), implying a +354.0% move over the next 12 months. The stock is currently near its 52-week low of $0.88, remaining 64.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $166,131↑ | $145,954↓ | $263,922↑ | $145,380↓ | $162,910 |
| Gross Profit | $120,828↑ | -$47,814↓ | $121,526↑ | $119,095↓ | $130,804 |
| Operating Income | -$6.20M↑ | -$9.21M↓ | -$7.66M↓ | -$7.01M↑ | -$8.06M |
| Net Income | -$6.28M↑ | -$9.14M↑ | -$25.75M↓ | -$5.89M↑ | -$7.73M |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...